Abcam (ABCZF) Institutional Ownership : 0.01% (As of May. 23, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Abcam Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Abcam's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Abcam's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Abcam's Float Percentage Of Total Shares Outstanding is 99.86%.

Abcam Institutional Ownership Historical Data

The historical data trend for Abcam's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Institutional Ownership Chart

Abcam Historical Data

The historical data trend for Abcam can be seen below:

	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29
Institutional Ownership	1.00	0.69	0.22	0.21	0.14	0.07	0.07	0.02	0.02	0.01

Abcam Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.